Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06511882 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

StatusRecruiting
PhasePhase 2
Started2024-11-07
View on ClinicalTrials.gov ↗

Amendment history

2026-02-24
Study Status v7
Primary completion date2026-08→2027-10
2026-02-18
4 amendments v3-v6
4 re-verifications since 2025-05-21, no change to tracked fields
2025-02-12
Study Status v2
Primary completion date2028-06→2026-08
Completion date2028-06→2028-08
2024-11-27
Study Status v1
Start date2024-06-28→2024-11-07
2024-07-16
Original filing
The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.
Trial Details
NCT Number NCT06511882
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: AbbVie
Conditions Acute Myeloid Leukemia
Enrollment 37 participants
Start Date 2024-11-07
Primary Completion 2027-10 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-27